Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients.
Willett, CG; Boucher, Y; Duda, DG; di Tomaso, E; Munn, LL; Tong, RT; Kozin, SV; Petit, L; Jain, RK; Chung, DC; Sahani, DV; Kalva, SP; Cohen, KS; Scadden, DT; Fischman, AJ; Clark, JW; Ryan, DP; Zhu, AX; Blaszkowsky, LS; Shellito, PC; Mino-Kenudson, M; Lauwers, GY
Volume / Issue
Start / End Page
Pubmed Central ID
International Standard Serial Number (ISSN)
Digital Object Identifier (DOI)